Ignite Creation Date:
2024-05-05 @ 4:38 PM
Last Modification Date:
2024-10-26 @ 9:22 AM
Study NCT ID:
NCT00281528
Status:
TERMINATED
Last Update Posted:
2019-11-22
First Post:
2006-01-24
Brief Title:
Weekly vs Every 2 Week vs Every 3 Week Administration of ABI-007 AbraxaneBevacizumab Combination in Metastatic Breast Cancer
Sponsor:
Celgene
Organization:
Celgene
Key Dates - Follows AllAPIJSON File Order
Start Date:
2006-02-01
Start Date Type:
ACTUAL
Primary Completion Date:
2010-07-01
Primary Completion Date Type:
ACTUAL
Completion Date:
2011-03-01
Completion Date Type:
ACTUAL
First Submit Date:
2006-01-24
First Submit QC Date:
January 24 2006
Study First Post Date:
2006-01-25
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
2012-03-13
Results First Post Date Type:
ESTIMATED
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2019-11-07
Last Update Post Date:
2019-11-22
Last Update Post Date Type:
ACTUAL